keyword
MENU ▼
Read by QxMD icon Read
search

malaria therapy

keyword
https://www.readbyqxmd.com/read/28539634/the-plasmodium-pi-4-k-inhibitor-kdu691-selectively-inhibits-dihydroartemisinin-pretreated-plasmodium-falciparum-ring-stage-parasites
#1
L Dembele, X Ang, M Chavchich, G M C Bonamy, J J Selva, M Yi-Xiu Lim, C Bodenreider, B K S Yeung, F Nosten, B M Russell, M D Edstein, J Straimer, D A Fidock, T T Diagana, P Bifani
Malaria control and elimination are threatened by the emergence and spread of resistance to artemisinin-based combination therapies (ACTs). Experimental evidence suggests that when an artemisinin (ART)-sensitive (K13 wild-type) Plasmodium falciparum strain is exposed to ART derivatives such as dihydroartemisinin (DHA), a small population of the early ring-stage parasites can survive drug treatment by entering cell cycle arrest or dormancy. After drug removal, these parasites can resume growth. Dormancy has been hypothesized to be an adaptive physiological mechanism that has been linked to recrudescence of parasites after monotherapy with ART and, possibly contributes to ART resistance...
May 24, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28539125/do-anti-malarials-in-africa-meet-quality-standards-the-market-penetration-of-non-quality-assured-artemisinin-combination-therapy-in-eight-african-countries
#2
Paul N Newton, Kara Hanson, Catherine Goodman
BACKGROUND: Quality of artemisinin-based combination therapy (ACT) is important for ensuring malaria parasite clearance and protecting the efficacy of artemisinin-based therapies. The extent to which non quality-assured ACT (non-QAACT), or those not granted global regulatory approval, are available and used to treat malaria in endemic countries is poorly documented. This paper uses national and sub-national medicine outlet surveys conducted in eight study countries (Benin, Kinshasa and Kantanga [Democratic Republic of the Congo, DRC], Kenya, Madagascar, Nigeria, Tanzania, Uganda and Zambia) between 2009 and 2015 to describe the non-QAACT market and to document trends in availability and distribution of non-QAACT in the public and private sector...
May 25, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28537265/a-tetraoxane-based-antimalarial-drug-candidate-that-overcomes-pfk13-c580y-dependent-artemisinin-resistance
#3
Paul M O'Neill, Richard K Amewu, Susan A Charman, Sunil Sabbani, Nina F Gnädig, Judith Straimer, David A Fidock, Emma R Shore, Natalie L Roberts, Michael H-L Wong, W David Hong, Chandrakala Pidathala, Chris Riley, Ben Murphy, Ghaith Aljayyoussi, Francisco Javier Gamo, Laura Sanz, Janneth Rodrigues, Carolina Gonzalez Cortes, Esperanza Herreros, Iñigo Angulo-Barturén, María Belén Jiménez-Díaz, Santiago Ferrer Bazaga, María Santos Martínez-Martínez, Brice Campo, Raman Sharma, Eileen Ryan, David M Shackleford, Simon Campbell, Dennis A Smith, Grennady Wirjanata, Rintis Noviyanti, Ric N Price, Jutta Marfurt, Michael J Palmer, Ian M Copple, Amy E Mercer, Andrea Ruecker, Michael J Delves, Robert E Sinden, Peter Siegl, Jill Davies, Rosemary Rochford, Clemens H M Kocken, Anne-Marie Zeeman, Gemma L Nixon, Giancarlo A Biagini, Stephen A Ward
K13 gene mutations are a primary marker of artemisinin resistance in Plasmodium falciparum malaria that threatens the long-term clinical utility of artemisinin-based combination therapies, the cornerstone of modern day malaria treatment. Here we describe a multinational drug discovery programme that has delivered a synthetic tetraoxane-based molecule, E209, which meets key requirements of the Medicines for Malaria Venture drug candidate profiles. E209 has potent nanomolar inhibitory activity against multiple strains of P...
May 24, 2017: Nature Communications
https://www.readbyqxmd.com/read/28536344/aptamer-technology-adjunct-therapy-for-malaria
#4
REVIEW
Nik Abdul Aziz Nik Kamarudin, Nurul Adila Mohammed, Khairul Mohd Fadzli Mustaffa
Malaria is a life-threatening parasitic infection occurring in the endemic areas, primarily in children under the age of five, pregnant women, and patients with human immunodeficiency virus and acquired immunodeficiency syndrome (HIV)/(AIDS) as well as non-immune individuals. The cytoadherence of infected erythrocytes (IEs) to the host endothelial surface receptor is a known factor that contributes to the increased prevalence of severe malaria cases due to the accumulation of IEs, mainly in the brain and other vital organs...
January 4, 2017: Biomedicines
https://www.readbyqxmd.com/read/28535809/safety-and-tolerability-of-adjunctive-rosiglitazone-treatment-for-children-with-uncomplicated-malaria
#5
Rosauro Varo, Valerie M Crowley, Antonio Sitoe, Lola Madrid, Lena Serghides, Rubao Bila, Helio Mucavele, Alfredo Mayor, Quique Bassat, Kevin C Kain
BACKGROUND: Despite the widespread use and availability of rapidly acting anti-malarials, the fatality rate of severe malaria in sub-Saharan Africa remains high. Adjunctive therapies that target the host response to malaria infection may further decrease mortality over that of anti-malarial agents alone. Peroxisome proliferator-activated receptor-gamma agonists (e.g. rosiglitazone) have been shown to act on several pathways implicated in the pathogenesis of severe malaria and may improve clinical outcome as an adjunctive intervention...
May 23, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28533179/polymorphisms-in-pfdhfr-and-pfdhps-genes-after-five-years-of-artemisinin-combination-therapy-act-implementation-from-urban-kolkata-india
#6
Moytrey Chatterjee, Swagata Ganguly, Pabitra Saha, Subhasish K Guha, Ardhendu Kumar Maji
BACKGROUND: In India, sulphadoxine-pyrimethamine (SP) is now in use as a partner drug of ACT (AS+SP) to treat uncomplicated falciparum malaria since 2010. Declined trend of AS+SP efficacy has been reported from north-eastern states of the country. It is not possible to determine the efficacy of SP alone from any study with ACT. So, this work was designed to study the pattern of polymorphisms in pfdhfr and pfdhps genes to predict the SP resistance status among parasite population of urban Kolkata after five years of ACT implementation...
May 19, 2017: Infection, Genetics and Evolution
https://www.readbyqxmd.com/read/28531845/artesunate-and-erythropoietin-synergistically-improve-the-outcome-of-experimental-cerebral-malaria
#7
Yunting Du, Guang Chen, Xuexing Zhang, Chunyun Yu, Yaming Cao, Liwang Cui
Cerebral malaria (CM) is a severe neurological syndrome in humans and the main fatal cause of malaria. In malaria epidemic regions, despite appropriate anti-malarial treatment, 10-20% of deaths still occur during the acute phase. This is largely attributable to poor treatment access, therapeutic complexity and drug resistance; thus, developing additional clinical adjunctive therapies is an urgent necessity. In this study, we investigated the effect of artesunate (AST) and recombinant human erythropoietin (rhEPO) using an experimental cerebral malaria (ECM) model-C57BL/6 mice infected with Plasmodium berghei ANKA (PbA)...
May 19, 2017: International Immunopharmacology
https://www.readbyqxmd.com/read/28531172/experimental-evaluation-of-cryopreservative-solutions-to-maintain-in-vitro-and-in-vivo-infectivity-of-p-berghei-sporozoites
#8
Naresh Singh, Samantha J Barnes, Sandra Kennedy, John H Adams
The rodent malaria parasite Plasmodium berghei is an excellent model organism for laboratory-based experimental evaluation of anti-malarial therapeutics prior to studies with human malaria parasites. The rodent model is especially important for evaluation of pre-erythrocytic (PE) stage therapies, especially as current efforts to develop new PE vaccines and drugs is limited by access to P. falciparum and P. vivax sporozoites. Developing a more effective method for cryopreservation of sporozoites would help improve access to sporozoites for laboratories lacking suitable insectary facilities...
2017: PloS One
https://www.readbyqxmd.com/read/28526075/testing-times-trends-in-availability-price-and-market-share-of-malaria-diagnostics-in-the-public-and-private-healthcare-sector-across-eight-sub-saharan-african-countries-from-2009-to-2015
#9
Kara Hanson, Catherine Goodman
BACKGROUND: The World Health Organization guidelines have recommended that all cases of suspected malaria should receive a confirmatory test with microscopy or a malaria rapid diagnostic test (RDT), however evidence from sub-Saharan Africa (SSA) illustrates that only one-third of children under five with a recent fever received a test. The aim of this study was to evaluate availability, price and market share of microscopy and RDT from 2009/11 to 2014/15 in 8 SSA countries, to better understand barriers to improving access to malaria confirmatory testing in the public and private health sectors...
May 19, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28521811/the-malaria-testing-and-treatment-landscape-in-mainland-tanzania-2016
#10
Daniel Michael, Sigsbert Patila Mkunde
BACKGROUND: Understanding the key characteristics of malaria testing and treatment is essential to the control of a disease that continues to pose a major risk of morbidity and mortality in mainland Tanzania, with evidence of a resurgence of the disease in recent years. The introduction of artemisinin combination therapy (ACT) as the first-line treatment for malaria, alongside policies to promote rational case management following testing, highlights the need for evidence of anti-malarial and testing markets in the country...
April 24, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28521791/exploring-the-role-of-socioeconomic-factors-in-the-development-and-spread-of-anti-malarial-drug-resistance-a-qualitative-study
#11
Philip Emeka Anyanwu, John Fulton, Etta Evans, Timothy Paget
BACKGROUND: Malaria remains a global health issue with the burden unevenly distributed to the disadvantage of the developing countries of the world. Poverty contributes to the malaria burden as it has the ability to affect integral aspects of malaria control. There have been renewed efforts in the global malaria control, resulting in reductions in the global malaria burden over the last decade. However, the development of resistance to artemisinin-based combination therapy threatens the sustainability of the present success in malaria control...
May 18, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28511713/artemisinin-based-combination-therapy-in-pregnant-women-in-zambia-efficacy-safety-and-risk-of-recurrent-malaria
#12
Michael Nambozi, Jean-Bertin Bukasa Kabuya, Sebastian Hachizovu, David Mwakazanga, Joyce Mulenga, Webster Kasongo, Jozefien Buyze, Modest Mulenga, Jean-Pierre Van Geertruyden, Umberto D'Alessandro
BACKGROUND: In Zambia, malaria is one of the leading causes of morbidity and mortality, especially among under five children and pregnant women. For the latter, the World Health Organization recommends the use of artemisinin-based combination therapy (ACT) in the second and third trimester of pregnancy. In a context of limited information on ACT, the safety and efficacy of three combinations, namely artemether-lumefantrine (AL), mefloquine-artesunate (MQAS) and dihydroartemisinin-piperaquine (DHAPQ) were assessed in pregnant women with malaria...
May 16, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28487425/a-variant-pfcrt-isoform-can-contribute-to-plasmodium-falciparum-resistance-to-the-first-line-partner-drug-piperaquine
#13
Satish K Dhingra, Devasha Redhi, Jill M Combrinck, Tomas Yeo, John Okombo, Philipp P Henrich, Annie N Cowell, Purva Gupta, Matthew L Stegman, Jonathan M Hoke, Roland A Cooper, Elizabeth Winzeler, Sachel Mok, Timothy J Egan, David A Fidock
Current efforts to reduce the global burden of malaria are threatened by the rapid spread throughout Asia of Plasmodium falciparum resistance to artemisinin-based combination therapies, which includes increasing rates of clinical failure with dihydroartemisinin plus piperaquine (PPQ) in Cambodia. Using zinc finger nuclease-based gene editing, we report that addition of the C101F mutation to the chloroquine (CQ) resistance-conferring PfCRT Dd2 isoform common to Asia can confer PPQ resistance to cultured parasites...
May 9, 2017: MBio
https://www.readbyqxmd.com/read/28480256/a-case-report-of-pediatric-brucellosis-in-an-algerian-immigrant
#14
Eimear Kitt, Kristina R Brannock, Lauren A VonHolz, Paul J Planet, Erin Graf, Vinodh Pillai
An 8-year old girl presented to our facility with a 10-day history of fever, fatigue, abdominal pain and refusal to walk. She recently travelled from her native Algeria where she first developed symptoms. On evaluation, she was ill-appearing, febrile and tachycardic with hepatosplenomegaly and lymphadenopathy noted on examination. A strong musty odor was also noted from the child. Laboratory evaluation revealed pancytopenia, hyponatremia, and an elevated AST, ALT, and LDH. Malaria testing was negative, as was a PPD...
2017: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/28480232/artemether-lumefantrine-and-dihydroartemisinin-piperaquine-exert-inverse-selective-pressure-on-plasmodium-falciparum-drug-sensitivity-associated-haplotypes-in-uganda
#15
Aimee R Taylor, Jennifer A Flegg, Chris C Holmes, Philippe J Guérin, Carol H Sibley, Melissa D Conrad, Grant Dorsey, Philip J Rosenthal
BACKGROUND: Altered sensitivity to multiple antimalarial drugs is mediated by polymorphisms in pfmdr1, which encodes the Plasmodium falciparum multidrug resistance transporter. In Africa the N86Y and D1246Y polymorphisms have been shown to be selected by treatment, with artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) selecting for wild-type and mutant alleles, respectively. However, there has been little study of pfmdr1 haplotypes, in part because haplotype analyses are complicated by multiclonal infections...
2017: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/28473165/unpacking-artemisinin-resistance
#16
REVIEW
Jigang Wang, Chengchao Xu, Zhao-Rong Lun, Steven R Meshnick
Artemisinin and its derivatives, in combination with partner drugs, are currently the most effective treatments for malaria parasite infection. Even though artemisinin has been widely used for decades, its mechanism of action had remained controversial until recently. Artemisinin combination therapies (ACTs) have recently been found to be losing efficacy in Southeast Asia. This 'artemisinin resistance', defined by a delayed parasite clearance time, has been associated with several genetic mutations. As with any other drug resistance phenotype, resistance can best be understood based on its mechanism of action...
May 1, 2017: Trends in Pharmacological Sciences
https://www.readbyqxmd.com/read/28472957/safety-and-efficacy-of-the-choline-analogue-sar97276-for-malaria-treatment-results-of-two-phase-2-open-label-multicenter-trials-in-african-patients
#17
Jana Held, Christian Supan, Carmen L Ospina Salazar, Halidou Tinto, Léa Nadège Bonkian, Alain Nahum, Ali Sié, Salim Abdulla, Cathy Cantalloube, Elhadj Djeriou, Marielle Bouyou-Akotet, Bernhards Ogutu, Benjamin Mordmüller, Andrea Kreidenweiss, Mohamadou Siribie, Sodiomon B Sirima, Peter G Kremsner
BACKGROUND: Malaria remains one of the most important infectious diseases. Treatment options for severe malaria are limited and the choline analogue SAR97276A is a novel chemical entity that was developed primarily as treatment for severe malaria. Before starting clinical investigations in severely ill malaria patients, safety and efficacy of SAR97276A was studied in patients with uncomplicated malaria. Here, we summarize two open-label, multi-center phase 2 trials assessing safety and efficacy of parenterally administered SAR97276A in African adults and children with falciparum malaria...
May 4, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28468663/evaluating-malaria-case-management-at-public-health-facilities-in-two-provinces-in-angola
#18
Mateusz M Plucinski, Manzambi Ferreira, Carolina Miguel Ferreira, Jordan Burns, Patrick Gaparayi, Lubaki João, Olinda da Costa, Parambir Gill, Claudete Samutondo, Joltim Quivinja, Eliane Mbounga, Gabriel Ponce de León, Eric S Halsey, Pedro Rafael Dimbu, Filomeno Fortes
BACKGROUND: Malaria accounts for the largest portion of healthcare demand in Angola. A pillar of malaria control in Angola is the appropriate management of malaria illness, including testing of suspect cases with rapid diagnostic tests (RDTs) and treatment of confirmed cases with artemisinin-based combination therapy (ACT). Periodic systematic evaluations of malaria case management are recommended to measure health facility readiness and adherence to national case management guidelines...
May 3, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28468628/impact-of-home-based-management-on-malaria-outcome-in-under-fives-presenting-in-a-tertiary-health-institution-in-nigeria
#19
Damian U Nwaneri, Ayebo E Sadoh, Michael O Ibadin
BACKGROUND: Home-based management of malaria involves prompt delivery of effective malaria treatment at the community by untrained caregiver. The aim of this study was to document home-based treatment of suspected malaria by non-medical caregivers and to identify its health impact on malaria outcome (severe malaria prevalence, parasite load and mortality) in children (6-59 months). METHODS: A descriptive cross-sectional study carried out from June 2012-July 2013...
May 3, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28467668/oxidative-stress-in-malaria-and-artemisinin-combination-therapy-pros-and-cons
#20
REVIEW
Reginald A Kavishe, Jan B Koenderink, Michael Alifrangis
Artemisinin-based combination therapy (ACT) has been adopted as a strategy to mitigate multidrug resistance to antimalarial monotherapies. ACT combines the rapid and effective but rather short plasma half-life antimalarial action of an artemisinin derivative with a longer acting partner drug. Although the exact mechanisms of action of artemisinins is not well understood, several studies have proposed multiple cellular targets of artemisinins with involvement of reactive oxygen species (ROS). Most of the currently used ACT partner drugs are also known to involve ROS production in their mechanisms of action...
May 3, 2017: FEBS Journal
keyword
keyword
79196
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"